Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Bob Duggan & Maky Zanganeh, Summit Therapeutics co-CEOs, join 'Fast Money' to talk its lung cancer drug and continuing ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced ...

Akeso and Summit Therapeutics' ivonescimab showed strong efficacy against Merck's Keytruda in a phase 3 trial in China. The ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, will present its ONCO Prime ...